The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Rubinstein
E
E
Infectious Diseases Unit and Department of Microbiology, Sheba Medical Center, Tel Aviv University, School of Medicine, Hashomer 52621, Israel.
Diamantstein
L
L
Yoseph
G
G
Gruzman
G
G
Rubinovitch
B
B
Barzilai
A
A
Keller
N
N
D000418:Albumins / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D002939:Ciprofloxacin / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects*; D004927:Escherichia coli Infections / Q000188:drug therapy; D024841:Fluoroquinolones; D005916:Globulins / Q000009:adverse effects; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009287:Naphthyridines / Q000494:pharmacology; D011008:Pneumococcal Infections / Q000188:drug therapy; D011804:Quinolines; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects*; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D013492:Suppuration / Q000473:pathology
D000418:Albumins; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D005916:Globulins; D009287:Naphthyridines; D011804:Quinolines; D002939:Ciprofloxacin; C080163:trovafloxacin; D000077266:Moxifloxacin